Press Releases

New York, New York--(Newsfile Corp. - May 16, 2024) - As Roland-Garros 2024 is getting closer, 7D Group, a luxury concierge and lifestyle management company, has announced its luxury accommodations offer. This is tailored to enhance the overall experience of the attendants at the prestigious tennis competition. This prestigious tennis tournament will kick off at Stade Roland Garros in Paris, from Monday, May 20, 2024, to Sunday, Jun 9, 2024.

Sasha Devic

Recognizing the... (continue reading...)

Sow Good (NASDAQ: SOWG), a trailblazer in the freeze dried candy and treat industry, recently announced that the underwriters of its completed public offering of common stock had purchased 180,000 shares of its common stock. The underwriters made the purchase upon full exercise of their option to purchase additional shares of common stock to cover overallotments at the initial offering price of $10.00 per unit. Including proceeds from the sale of additional shares, the... (continue reading...)

Arrowhead Sci-Tech Conferences and Events today announced the 4th Annual Psychedelic Therapeutics and Drug Development Conference, the flagship event for research and therapeutics development in the psychedelics space. The event will be held May 23-24, 2024, at the iconic Revere Hotel Boston Common in Boston, MA. The two-day event is expected to attract the world’s leading researchers and thought leaders in academia, industry, the non-profit sector, and government... (continue reading...)

Quinton Rendell Triumphs in Comeback Fight and Sabrina Francis Rocks the Island Grenada

SAN DIEGO, CA / ACCESSWIRE / May 16, 2024 / TPT Global Tech, Inc. (OTCQB: TPTW), a trailblazer in technology and telecommunications, proudly announces the successful broadcast of two live broadcast events on its V�Me Live PPV platform. On May 3rd and 4th, the inaugural V�Me Boxing event, "Rumble in Humble," captivated audiences with a thrilling display of talent and tenacity.... (continue reading...)

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, is reporting its financial and business results for the first quarter 2024, the period ended March 31, 2024. A highlight of the report was that enrollment is nearly completed in a potentially pivotal GBM study evaluating Berubicin with topline data expected in the first half of... (continue reading...)